Navigation Links
MIV-711 Osteoarthritis Trial: Successful Fourth Independent Review of Safety Data Enables Trial Continuation Without any Modifications
Date:2/1/2017

STOCKHOLM, Sweden, Feb. 01, 2017 /PRNewswire/ --Medivir AB (Nasdaq Stockholm: MVIR) today announces that the independent Data Monitoring Committee (DMC) held its fourth and final scheduled meeting and recommended continuation of the ongoing randomized, double-blind phase IIa study (MIV-711-201) based on a review of unblinded safety data

The objective of MIV-711-201 is to evaluate the safety, tolerability and efficacy of six months of treatment with MIV-711 in patients with moderate knee osteoarthritis. As part of the study, an independent DMC is periodically scheduled to review the unblinded safety data from the trial. Based on the last scheduled review of the accumulated safety data, which took place after the first 200 subjects had completed 3 months of treatment, the DMC has recommended that the phase IIa trial of osteoarthritis should continue without any modifications.

It is expected that data from MIV-711-201 will be available in the third quarter of 2017 and that data from the ongoing extension study, MIV-711-202, will be available in the first half of 2018.

MIV-711 is being developed as a DMOAD, i.e. a drug to slow or reverse the progressive degeneration of joints affected by OA. There are no DMOADs approved for use currently, and the standard of care for OA patients is based on analgesics, with the potential for associated side effect risks such as gastrointestinal bleeding and opioid dependency, and changes in life style. DMOADs for osteoarthritis therefore represent a very large and attractive market opportunity. Medivir estimates that the US market alone is greater than USD 6 billion annually for a drug that impacts disease progression, even if its use was restricted just to patient populations with moderate osteoarthritis in weight-bearing joints.

Further information on the study can be accessed on www.clinicaltrials.gov, ref# NCT02705625.

For further information, please contact:

Richard Bethell, CSO Medivir AB, mobile +46 (0)72-704 3211
Ola Burmark, CFO Medivir AB, mobile: +46 (0) 725 480 580

This information is information that Medivir AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 08.30 CET on 1 February 2017.

About Medivir

Medivir is a research based pharmaceutical company with a focus on oncology. We have a leading competence within protease inhibitor design and nucleotide/nucleoside science and we are dedicated to develop innovative pharmaceuticals that meet great unmet medical need. Medivir's class B share is listed on the Nasdaq Stockholm Mid Cap List.

CONTACT:

This information was brought to you by Cision http://news.cision.com
http://news.cision.com/medivir/r/miv-711-osteoarthritis-trial--successful-fourth-independent-review-of-safety-data-enables-trial-cont,c2178118

The following files are available for download:

http://mb.cision.com/Main/652/2178118/622108.pdf

Press release (PDF)

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/miv-711-osteoarthritis-trial-successful-fourth-independent-review-of-safety-data-enables-trial-continuation-without-any-modifications-300400247.html


'/>"/>
SOURCE Medivir
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Increasing Prevalence of Osteoarthritis and Preference for Minimally Invasive Procedures to Drive Arthroscopy Devices Market Growth
2. Ampio Pharmaceuticals, Inc. Announces Positive Results for Ampion in Osteoarthritis of the Knee Clinical Trial
3. Cellular Biomedicine Group Announces Positive Interim Results from Phase I/IIa Clinical Trial for Treatment of Knee Osteoarthritis (KOA)
4. Ampio Pharmaceuticals, Inc. Announces Additional Positive Results for Ampion(TM) in Osteoarthritis of the Knee Clinical Trial
5. Highland Instruments, Inc., Announces Presentation of "Effects of Electrosonic Stimulation on the Perception of Chronic Pain Due to Osteoarthritis of the Knee."
6. September is National Aging Month: Resources Available on Importance of Treatment for Cataracts, Osteoarthritis and Diabetes
7. Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis
8. Pharmalink Acquires Novel Therapeutic Product Candidate for Treating Inflammation Associated With Osteoarthritis
9. Global Osteoarthritis Market 2015-2019 - Increased Competition in the Market With Abbott Laboratories, Johnson & Johnson, Novartis & Pfizer Dominating
10. Townsend Announces Launch Of New Osteoarthritis Knee Brace
11. Ampio Pharmaceuticals Announces Update of STRIDE Study for the Investigation of Pain Associated with Osteoarthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2018)... ... August 15, 2018 , ... ... solutions, announced today that athenahealth, a leading provider of network-enabled services for ... solution for its IQR program requirements. The Drummond-certified program will enable athenahealth ...
(Date:8/14/2018)... TAMPA, Fla. (PRWEB) , ... August 14, 2018 ... ... nation’s largest faith-based health care systems, with nearly 50 hospital campuses and more ... name change, the health system will move to being one consumer-centric, connected and ...
(Date:8/11/2018)... ... 10, 2018 , ... US Capital Global has been retained by ... round. Carepoynt is an emerging leader in the digital health field. The company is ... engaging healthcare ecosystem. , Headquartered in San Francisco, US Capital Global is a full-service ...
Breaking Medicine Technology:
(Date:8/15/2018)... ... August 15, 2018 , ... Today David Hyde Apparel debuts ... , Born out of a desire for confidence and comfort year-round, the new ... odor – even in the hottest, most humid of climates. , The brainchild of ...
(Date:8/15/2018)... , ... August 15, 2018 , ... ... Amber Valentino, Psy.D., BCBA-D, to associate editor of Behavior Analysis in Practice, one ... is currently the chief clinical standards and research officer for Trumpet, leading the ...
(Date:8/14/2018)... DIEGO (PRWEB) , ... August 14, 2018 , ... ... University, will be the keynote speaker at ChiroTouch Connect User Conference. The ChiroTouch ... the Florida Chiropractic Association (FCA). , ChiroTouch is ecstatic to have Kathy ...
(Date:8/14/2018)... ... ... Health & hygiene ranked eighth out of 15 industries analyzed ... brands based on emotions. In the U.S., Olay again topped the industry, followed by ... hygiene industry were: Listerine, Nivea, Gillette, Colgate, Head & Shoulders, Pantene and Crest. , ...
(Date:8/14/2018)... ... August 14, 2018 , ... Eagle Merchant Partners and ... provider of residential and commercial recreational surfacing products across the country. , The ... used across a wide range of markets and customers. Founded in 1998, Recreational ...
Breaking Medicine News(10 mins):